Condensed Consolidated Statements of Cash Flows (Unaudited) - USD ($) $ in Thousands	3 Months Ended		6 Months Ended
	Jun. 30, 2025	Jun. 30, 2024	Jun. 30, 2025	Jun. 30, 2024
Operating activities:
Net loss	$ 39,746	$ (25,261)	$ 12,776	$ (34,091)
Adjustments to reconcile net income (loss) to net cash used in operating activities:
Depreciation and amortization			431	778
Stock-based compensation			1,828	2,175
Non-cash operating lease expense			901	714
Loss on amendment and cancellation of warrants	0	0	2,073	0
Loss on execution of the 2025 PIPE	0	0	71,084	0
Transaction costs allocated to pre-funded warrants and warrants issued in connection with the 2025 PIPE and 2024 PIPE			2,777	1,507
Change in fair value of tranche liability			(47,860)	0
Change in fair value of warrant liabilities			(56,698)	(5,036)
Loss on issuance of common stock, pre-funded warrants and warrants in the 2024 PIPE			0	20,397
Gain on settlement of tranche liability	0	0	(1,117)	0
Non-cash consideration received in connection with research service revenue			(462)	0
(Gain) loss on foreign currency remeasurement			(278)	40
Changes in operating assets and liabilities:
Accounts receivable-related party			250	0
Prepaid expenses and other current assets			763	1,177
Other assets			36	29
Accounts payable			48	(352)
Accrued and other liabilities			(989)	(482)
Operating Lease liabilities			(955)	(1,213)
Net cash used in operating activities			(15,392)	(14,357)
Investing activities:
Purchases of property and equipment			(45)	(7)
Net cash used in investing activities			(45)	(7)
Financing activities:
Proceeds from issuance of common stock, pre-funded warrants and warrants in the 2025 PIPE and 2024 PIPE, net of transaction costs			71,201	16,044
Proceeds from issuance of common stock under employee stock purchase plan			61	42
Net cash provided by financing activities			71,262	16,086
Net increase in cash, cash equivalents and restricted cash			55,825	1,722
Cash, cash equivalents and restricted cash at beginning of period			35,253	36,731
Cash, cash equivalents and restricted cash at end of period	91,078	38,453	91,078	38,453
Supplemental disclosure of noncash investing and financing activities:
Issuance of common stock upon exercise of warrants			677	0
Vesting of early exercises of stock options			0	1
Reconciliation Of Cash Cash Equivalents And Restricted Cash To Consolidated Balance Sheets Abstract
Cash and cash equivalents	90,390	37,765	90,390	37,765
Restricted cash	688	688	688	688
Cash, cash equivalents and restricted cash	$ 91,078	$ 38,453	$ 91,078	$ 38,453